An Evaluation of Glycemic Control Effects of Mono Therapy CKD-501 in Patients With Type 2 Diabetes Mellitus

NCT01001611 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

173

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: CKD-501 0.5mg
DRUG: Placebo

Sponsor

Chong Kun Dang Pharmaceutical